The Food and Drug Administration has approved a second biosimilar competitor for Amgen’s blockbuster rheumatoid arthritis drug Enbrel. Korean biopharmaceutical company Samsung Bioepis’ biosimilar, called Eticovo, was approved to treat all the conditions treated by Enbrel. Amgen’s top-selling drug, Enbrel brought in just over $5 billion for the Thousand Oaks biotech giant in 2018, down…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
